PresseBox
Press release BoxID: 154700 (Speedel Pharma AG)
  • Speedel Pharma AG
  • Hirschgässlein 11
  • 4051 Basel
  • http://www.speedel.com
  • Contact person
  • Frank LaSaracina
  • +1 (732) 537-2290

Change in Management Team

Director of Communications and Investor Relations Leaves Company

(PresseBox) (Basel/Switzerland and Bridgewater NJ/USA, ) Speedel Holding Ltd (SWX: SPPN) today announced that its Director of Communications and Investor Relations, Nick Miles, is leaving the company. Nick Miles joined Speedel in 2003, when it still was a privately held company, and was responsible for the development of the Company's communication and investor relations through its becoming a public company in 2005.

Konrad P. Wirz, CFO stated: "With his professional expertise and communication skills, Nick Miles was very instrumental during the company's transition from a private to a public company and beyond. We wish Nick well in his future endeavours".

For an interim period, Konrad P. Wirz, CFO of Speedel, will head the team of Communications and Investor Relations within Speedel.

Speedel Pharma AG

Speedel is a public biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead compound SPP100, Aliskiren (Rasilez/Tekturna[1]) the first-in-class direct renin inhibitor, was in-licensed from Novartis in 1999 and licensed-back to Novartis Pharma in 2002 for further development and commercialisation; SPP100 was approved by the FDA in the US in March 2007, and by the EMEA in the EU in August 2007. Our pipeline covers four different modes of action, and in addition to SPP100, includes SPP301 (an endothelin receptor A antagonist) in Phase II, SPP200 (a direct thrombin inhibitor) in Phase II, the next generation renin inhibitors SPP635 (in Phase Il), SPP1148 and SPP676 (both in Phase I) and several pre-clinical projects, including SPP2745 (aldosterone synthase inhibitor).

Speedel develops novel product candidates through focused innovation and smart drug development from lead identification to the end of Phase II. We either partner with big pharma for Phase III and commercialisation in primary-care indications, or we may ourselves complete Phase III development in specialist indications. Candidate compounds for development and the company's intellectual property come from our late-stage research unit Speedel Experimenta and from in-licensing. Our team of approximately 80 employees, including over 30 experienced pharmaceutical scientists, is located at our headquarters and laboratories in Basel, Switzerland and at offices in New Jersey, USA and Tokyo, Japan.

Speedel was founded in 1998 as a private company. In September 2005 the company's shares were listed on the SWX Swiss Exchange under the symbol SPPN. Further information is available at www.speedel.com.